The synergistic use of gene therapy and chemotherapy drugs has characteristics such as simultaneous blockade of multiple pathways, complementary therapeutic targets, and increased drug sensitivity [130,131,132,133,134].Combination therapy and pathway-synergistic strategies targeting RASSF4 have been explored in preclinical studies, and RASSF4 overexpression significantly enhances tumor cell sensitivity to traditional chemotherapy drugs. The gene discussed is RASSF4; the disease is neoplasm.